Lisocabtagene maraleucel (Breyanzi^®) was first approved by the U.S. Food and Drug Administration (FDA) in 2021 for patients with relapsed or refractory large B-cell lymphoma (LBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade IIIB follicular lymphoma. In 2022, the FDA expanded its approval for the initial indication to include those with refractory disease or relapse within 12 months of first-line chemoimmunotherapy who are not eligible for hematopoietic stem cell transplantation.

In May 2023, the U.S. Food and Drug Administration (FDA) announced it had granted accelerated approval for the first CD20 bispecific antibody drug, epcoritamab-bysp (Epkinly^™) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In June 2024, the FDA expanded the indication with accelerated approval for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.